Contrasting Catalyst Pharmaceuticals (NASDAQ:CPRX) and Chimerix (CMRX)

Catalyst Pharmaceuticals (NASDAQ: CPRX) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider and Institutional Ownership

40.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Chimerix shares are owned by institutional investors. 8.8% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Catalyst Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Catalyst Pharmaceuticals and Chimerix, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Pharmaceuticals 0 0 4 0 3.00
Chimerix 0 2 0 0 2.00

Catalyst Pharmaceuticals currently has a consensus price target of $5.50, suggesting a potential upside of 91.64%. Chimerix has a consensus price target of $6.50, suggesting a potential upside of 32.65%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Chimerix.

Valuation & Earnings

This table compares Catalyst Pharmaceuticals and Chimerix’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Catalyst Pharmaceuticals N/A N/A -$18.07 million ($0.21) -13.67
Chimerix $5.70 million 40.52 -$76.39 million ($1.43) -3.43

Catalyst Pharmaceuticals has higher revenue, but lower earnings than Chimerix. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Catalyst Pharmaceuticals and Chimerix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalyst Pharmaceuticals N/A -48.86% -45.62%
Chimerix -1,440.67% -26.00% -25.10%

Summary

Catalyst Pharmaceuticals beats Chimerix on 8 of the 12 factors compared between the two stocks.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.

Chimerix Company Profile

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply